Genomic Meta-analysis of Clear-cell Renal Cell Carcinoma (ccRCC): Aggregating Tumors to Resolve the Complexity of ccRCC

Affiliations

¹ Department of Urology, University of Carolina at Chapel Hill, Chapel Hill, NC, USA.
² Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
³ Department of Urology, University of Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: ibardo_zambrano@med.unc.edu.

Editorial

Kathryn H Gessner et al. Eur Urol. 2022 Apr.

. 2022 Apr;81(4):362-363.

doi: 10.1016/j.eururo.2022.01.003. Epub 2022 Jan 24.

¹ Department of Urology, University of Carolina at Chapel Hill, Chapel Hill, NC, USA.
² Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
³ Department of Urology, University of Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: ibardo_zambrano@med.unc.edu.

No abstract available

Comment on

Genomics of Clear-cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
Bui TO, Dao VT, Nguyen VT, Feugeas JP, Pamoukdjian F, Bousquet G. Bui TO, et al. Eur Urol. 2022 Apr;81(4):349-361. doi: 10.1016/j.eururo.2021.12.010. Epub 2022 Jan 3. Eur Urol. 2022. PMID: 34991918

1. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013;499:43–9. - PMC - PubMed
1. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883–92. - PMC - PubMed
1. Bui TO, Dao VT, Nguyen VT, Feugeas JP, Pamoukdjian F, Bousquet G. Genomics of clear-cell renal cell carcinoma: a systematic review and meta-analysis. Eur Urol 2022;81:349–61. - PubMed
1. Bailey ST, Smith AM, Kardos J, et al. MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma. Nat Commun 2017;8:15770. - PMC - PubMed
1. McDermott DF, Huseni MA, Atkins MB, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med 2018;24:749–57. - PMC - PubMed